Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0PG5G
|
||||
| Former ID |
DAP000107
|
||||
| Drug Name |
Infliximab
|
||||
| Synonyms |
Remicade (TN)
|
||||
| Drug Type |
Antibody
|
||||
| Indication | Crohn's disease; Ulcerative colitis; Rheumatoid arthritis; Ankylosing spondylitis; Psoriatic arthritis; Plaque psoriasis [ICD10:K50.0, K51.90, M05.9, M45.3, L40.52, L40] | Approved | [468124], [536688], [889446] | ||
| Asthma [ICD10:J45] | Phase 3 | [468124], [536711] | |||
| Rheumatoid arthritis; Dermatomyositis; Polymyositis; Juvenile rheumatoid arthritis; Graft-versus-host disease; Esophagitis [ICD10:K20, L40, M05-M06, M08.0, T86.0] | Phase 2 | [889320], [889321], [889322], [889325], [889335], [889336], [889337], [889342], [889347], [889355] | |||
| Therapeutic Class |
Immunosuppressive Agents
|
||||
| Company |
Samsung Bioepsis
|
||||
| Formula |
C6428H9912N1694O1987S46
|
||||
| CAS Number |
CAS 170277-31-3
|
||||
| SuperDrug ATC ID |
L04AB02
|
||||
| Target and Pathway | |||||
| Target(s) | Tumor necrosis factor | Target Info | [536688] | ||
| KEGG Pathway | MAPK signaling pathway | ||||
| Cytokine-cytokine receptor interaction | |||||
| NF-kappa B signaling pathway | |||||
| Sphingolipid signaling pathway | |||||
| mTOR signaling pathway | |||||
| Apoptosis | |||||
| TGF-beta signaling pathway | |||||
| Osteoclast differentiation | |||||
| Antigen processing and presentation | |||||
| Toll-like receptor signaling pathway | |||||
| NOD-like receptor signaling pathway | |||||
| RIG-I-like receptor signaling pathway | |||||
| Hematopoietic cell lineage | |||||
| Natural killer cell mediated cytotoxicity | |||||
| T cell receptor signaling pathway | |||||
| Fc epsilon RI signaling pathway | |||||
| TNF signaling pathway | |||||
| Adipocytokine signaling pathway | |||||
| Type II diabetes mellitus | |||||
| Non-alcoholic fatty liver disease (NAFLD) | |||||
| Type I diabetes mellitus | |||||
| Alzheimer's disease | |||||
| Amyotrophic lateral sclerosis (ALS) | |||||
| Pertussis | |||||
| Legionellosis | |||||
| Leishmaniasis | |||||
| Chagas disease (American trypanosomiasis) | |||||
| African trypanosomiasis | |||||
| Malaria | |||||
| Toxoplasmosis | |||||
| Amoebiasis | |||||
| Tuberculosis | |||||
| Hepatitis C | |||||
| Hepatitis B | |||||
| Influenza A | |||||
| HTLV-I infection | |||||
| Herpes simplex infection | |||||
| Proteoglycans in cancer | |||||
| Asthma | |||||
| Inflammatory bowel disease (IBD) | |||||
| Systemic lupus erythematosus | |||||
| Rheumatoid arthritis | |||||
| Allograft rejection | |||||
| Graft-versus-host disease | |||||
| Hypertrophic cardiomyopathy (HCM) | |||||
| Dilated cardiomyopathy | |||||
| PANTHER Pathway | Apoptosis signaling pathway | ||||
| Wnt signaling pathway | |||||
| Pathway Interaction Database | IL27-mediated signaling events | ||||
| Canonical NF-kappaB pathway | |||||
| Calcineurin-regulated NFAT-dependent transcription in lymphocytes | |||||
| Angiopoietin receptor Tie2-mediated signaling | |||||
| Signaling events mediated by HDAC Class I | |||||
| TNF receptor signaling pathway | |||||
| Ceramide signaling pathway | |||||
| amb2 Integrin signaling | |||||
| RXR and RAR heterodimerization with other nuclear receptor | |||||
| IL23-mediated signaling events | |||||
| HIV-1 Nef: Negative effector of Fas and TNF-alpha | |||||
| Caspase Cascade in Apoptosis | |||||
| Cellular roles of Anthrax toxin | |||||
| Downstream signaling in naï | |||||
| PathWhiz Pathway | Fc Epsilon Receptor I Signaling in Mast Cells | ||||
| WikiPathways | Toll-like receptor signaling pathway | ||||
| Monoamine Transport | |||||
| SIDS Susceptibility Pathways | |||||
| TGF Beta Signaling Pathway | |||||
| Cytokines and Inflammatory Response | |||||
| MAPK Signaling Pathway | |||||
| EV release from cardiac cells and their functional effects | |||||
| FAS pathway and Stress induction of HSP regulation | |||||
| Apoptosis-related network due to altered Notch3 in ovarian cancer | |||||
| Cardiac Hypertrophic Response | |||||
| Transcriptional Regulation of White Adipocyte Differentiation | |||||
| Aryl Hydrocarbon Receptor | |||||
| Apoptosis | |||||
| Nanoparticle triggered regulated necrosis | |||||
| Amyotrophic lateral sclerosis (ALS) | |||||
| Adipogenesis | |||||
| Allograft Rejection | |||||
| TNF alpha Signaling Pathway | |||||
| TWEAK Signaling Pathway | |||||
| Extrinsic Pathway for Apoptosis | |||||
| Folate Metabolism | |||||
| MicroRNAs in cardiomyocyte hypertrophy | |||||
| Vitamin B12 Metabolism | |||||
| Selenium Micronutrient Network | |||||
| Regulation of toll-like receptor signaling pathway | |||||
| Matrix Metalloproteinases | |||||
| References | |||||
| Ref 468124 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5004). | ||||
| Ref 536688 | Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat Clin Pract Rheumatol. 2008 Jun;4(6):300-9. Epub 2008 Apr 15. | ||||
| Ref 536711 | Molecular targets of rheumatoid arthritis. Inflamm Allergy Drug Targets. 2008 Mar;7(1):53-66. | ||||
| Ref 889320 | ClinicalTrials.gov (NCT00006292) Infliximab for the Treatment of Early Rheumatoid Arthritis | ||||
| Ref 889321 | ClinicalTrials.gov (NCT00029042) Infliximab to Treat Children With Juvenile Rheumatoid Arthritis | ||||
| Ref 889322 | ClinicalTrials.gov (NCT00033891) Infliximab (Remicade ) to Treat Dermatomyositis and Polymyositis | ||||
| Ref 889325 | ClinicalTrials.gov (NCT00076726) A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Giant Cell Arteritis | ||||
| Ref 889335 | ClinicalTrials.gov (NCT00201799) Infliximab for the Prevention of Graft-versus-Host Disease Following Allogenic Hematopoietic Stem Cell Transplantation | ||||
| Ref 889336 | ClinicalTrials.gov (NCT00230529) A Safety and Efficacy Study of Infliximab (Remicade) in Patients With Plaque Type Psoriasis | ||||
| Ref 889337 | ClinicalTrials.gov (NCT00244192) Effects of Infliximab (Remicade) on Fat Free Mass in Patients With Moderate to Severe COPD Suffering From Cachexia | ||||
| Ref 889342 | ClinicalTrials.gov (NCT00443222) Treatment With TNF Blockade, Infliximab, in Patients With Myositis | ||||
| Ref 889347 | ClinicalTrials.gov (NCT00523354) Off Label Use of Infliximab in Adult Patients With Severe Eosinophilic Esophagitis | ||||
| Ref 889355 | ClinicalTrials.gov (NCT00823641) The HAM Infliximab Study | ||||
| Ref 889446 | Drugs@FDA (Edaravone) | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.